Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Doxorubicin-formaldehyde conjugates targeting alphavbeta3 integrin.

David J Burkhart1, Brian T Kalet, Michael P Coleman

  • 1Department of Chemistry and Biochemistry, University of Colorado, Boulder, Colorado 80309-0215, USA.

Molecular Cancer Therapeutics
|January 7, 2005
PubMed
Summary

Researchers developed targeted cancer prodrugs by linking doxorubicin to tumor-homing peptides. These conjugates release active drug at the tumor site, showing promise for reduced side effects and effective cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The TLR7/8 agonist INI-4001 enhances the immunogenicity of a Powassan virus-like-particle vaccine.

NPJ vaccines·2025
Same author

Encapsulation of the lipidated TLR7/8 agonist INI-4001 into ionic liposomes impacts H7 influenza antigen-specific immune responses.

Drug delivery and translational research·2025
Same author

SARM1 activation induces reversible mitochondrial dysfunction and can be prevented in human neurons by antisense oligonucleotides.

Neurobiology of disease·2025
Same author

A novel cationic liposome-formulated toll like receptor (TLR) 7/8 agonist enhances the efficacy of a vaccine against fentanyl toxicity.

Journal of controlled release : official journal of the Controlled Release Society·2025
Same author

The TLR7/8 agonist INI-4001 enhances the immunogenicity of a Powassan virus-like-particle vaccine.

bioRxiv : the preprint server for biology·2024
Same author

Chronically Low NMNAT2 Expression Causes Sub-lethal SARM1 Activation and Altered Response to Nicotinamide Riboside in Axons.

Molecular neurobiology·2024

Area of Science:

  • Medicinal Chemistry
  • Oncology
  • Pharmacology

Background:

  • Doxorubicin is a potent chemotherapy agent with significant side effects.
  • Prodrug strategies can improve drug delivery and reduce toxicity.
  • Integrin alphavbeta3 is overexpressed in many tumors, making it a target for drug delivery.

Purpose of the Study:

  • To synthesize and evaluate novel doxorubicin prodrug conjugates targeted to alphavbeta3 integrin.
  • To assess the binding affinity and anti-cancer activity of these conjugates.
  • To investigate the mechanism of drug release and cellular uptake.

Main Methods:

  • Synthesis of doxsaliform-peptide conjugates using hydroxylamine ether tethers and oxime linkages.
  • Evaluation of alphavbeta3 binding affinity using vitronectin cell adhesion assays.

Related Experiment Videos

  • Assessment of anti-cancer activity against MDA-MB-435 breast cancer cells via growth inhibition assays and flow cytometry.

    • Main Results:

    • Acyclic RGD-4C-doxsaliform conjugate showed good alphavbeta3 binding (IC50 = 10 nmol/L) and cancer cell growth inhibition (IC50 = 50 nmol/L).
    • Cyclic-(N-Me-VRGDf-NH)-doxsaliform conjugate maintained high alphavbeta3 affinity (IC50 = 5 nmol/L) but had higher growth inhibition IC50 (90 nmol/L).
    • Evidence suggests the active metabolite is released after cellular uptake, not the intact conjugate.

    Conclusions:

    • Doxsaliform-peptide conjugates effectively target alphavbeta3 integrin and inhibit cancer cell growth.
    • The drug construct's design facilitates targeted release of the active metabolite within tumor cells.
    • These targeted conjugates represent promising candidates for further in vivo evaluation with reduced systemic toxicity.